insulin detemir + sitagliptin

**Insulin detemir + sitagliptin** is a combination therapy for the management of type 2 diabetes mellitus. Insulin detemir is a long-acting recombinant human insulin analog; sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor. This combination aims to improve glycemic control by leveraging two complementary mechanisms: - Insulin detemir binds to the insulin receptor, activating intracellular signaling cascades (PI3K-Akt pathway) to promote cellular uptake of glucose and inhibit hepatic glucose production[2]. - Sitagliptin inhibits DPP-4, resulting in increased levels of incretin hormones (GLP-1, GIP), which enhance glucose-dependent insulin secretion, suppress glucagon release, and decrease endogenous glucose production[4][8]. Clinical studies show that adding sitagliptin to insulin detemir therapy leads to improved HbA1c reduction, reduced day-to-day glucose variability, and typically does not cause significant weight gain or increased risk of hypoglycemia compared to insulin alone[1][3][7]. This combination is used in patients with type 2 diabetes not adequately controlled by monotherapy[3][7].

Other names

insulin detemir plus sitagliptin